Treatment for Asthma with Daily Symptoms
For patients with daily asthma symptoms (indicating at least moderate persistent asthma), the preferred treatment is a low-dose inhaled corticosteroid (ICS) plus a long-acting beta agonist (LABA), specifically ICS-formoterol as both maintenance and reliever therapy (MART). 1
Understanding Your Patient's Severity
Daily symptoms indicate you are beyond Step 1 (intermittent asthma) and at minimum Step 3 (moderate persistent asthma) in the NAEPP stepwise approach. The key indicator here is that using a short-acting beta agonist more than two days per week for symptom relief signals inadequate control and the need for controller therapy. 1
Recommended Treatment Algorithm
First-Line Preferred Therapy (Step 3):
Low-dose ICS-formoterol combination taken as:
- Maintenance dosing: Regular daily use
- Reliever dosing: As-needed for breakthrough symptoms 1
Alternative option: Medium-dose ICS alone 1
If ICS-LABA Combination is Not Tolerated:
Alternative controllers (in order of preference):
- Low-dose ICS plus leukotriene receptor antagonist (montelukast or zafirlukast) 1
- Low-dose ICS plus theophylline (requires serum level monitoring) 1
- Low-dose ICS plus zileuton (requires liver function monitoring) 1
Critical Safety Warning:
Never use long-acting beta agonists as monotherapy. LABAs must always be combined with ICS, as monotherapy has been associated with increased severe exacerbations and deaths. 1 If you need to increase therapy, consider increasing the ICS dose before adding other agents.
Essential Concurrent Management
At every step, ensure:
- Patient education about disease and medication use 1
- Environmental control measures (allergen avoidance when relevant) 1
- Management of comorbidities 1
- Verification of proper inhaler technique 1
- Assessment of medication adherence 1
For allergic asthma (Steps 2-4): Consider subcutaneous allergen immunotherapy 1
Quick-Relief Medication
All patients need: Short-acting beta agonist (SABA) for rescue therapy, though with ICS-formoterol MART, the same inhaler serves both purposes 1
When to Step Up Treatment
If symptoms remain uncontrolled on Step 3 therapy, advance to Step 4:
- Preferred: Medium-dose ICS plus LABA 1
- Alternative: Medium-dose ICS plus leukotriene receptor antagonist, theophylline, or zileuton 1
Before stepping up, always verify:
- Medication adherence
- Proper inhaler technique
- Environmental trigger control
- Comorbid condition management 1
Common Pitfalls to Avoid
Do not:
- Prescribe SABA alone for persistent asthma with daily symptoms—this is inadequate and dangerous 1
- Use LABA without ICS 1
- Forget to provide a written asthma action plan 2
- Neglect to check if the patient can actually use their prescribed inhaler device 1
Do:
- Reassess control regularly using validated tools
- Step down therapy after 3 months of good control 1
- Consider referral to a specialist if control is not achieved at Step 4 or higher 3
Special Populations
For patients unable or unwilling to use ICS: Leukotriene receptor antagonists (montelukast once daily or zafirlukast twice daily) are appropriate alternatives for mild persistent asthma, though they are less effective than ICS. 1 However, with daily symptoms suggesting moderate disease, ICS-containing therapy is strongly preferred.
In certain ethnic populations (particularly Black patients): There may be genetic variations affecting LABA response, though recent research questions the clinical significance. 1 This doesn't change the recommendation but warrants closer monitoring.
Growth Considerations in Children
While the evidence shows ICS-containing therapy is essential, daily ICS (budesonide and beclomethasone) may cause modest growth suppression compared to intermittent use. 4 However, uncontrolled asthma poses greater risks to morbidity and mortality than the small growth effect, making daily controller therapy the appropriate choice for persistent symptoms.